1302 Stock Overview
An investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
LifeTech Scientific Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.93 |
| 52 Week High | HK$3.02 |
| 52 Week Low | HK$1.56 |
| Beta | 0.74 |
| 1 Month Change | 16.97% |
| 3 Month Change | 8.43% |
| 1 Year Change | -22.18% |
| 3 Year Change | n/a |
| 5 Year Change | 32.19% |
| Change since IPO | 7.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1302 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | 12.2% | 1.7% | 4.1% |
| 1Y | -22.2% | -42.2% | -2.2% |
Return vs Industry: 1302 exceeded the Hong Kong Medical Equipment industry which returned -42.2% over the past year.
Return vs Market: 1302 underperformed the Hong Kong Market which returned -2.2% over the past year.
Price Volatility
| 1302 volatility | |
|---|---|
| 1302 Average Weekly Movement | 5.5% |
| Medical Equipment Industry Average Movement | 7.5% |
| Market Average Movement | 7.5% |
| 10% most volatile stocks in HK Market | 15.2% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 1302 has not had significant price volatility in the past 3 months.
Volatility Over Time: 1302's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 1,448 | Yuehui Xie | www.lifetechmed.com |
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders worldwide. The company operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac Pacing and Electrophysiology Business segments. Its products include LAmbre left atrial appendage closure systems, as well as CeraFlex, Cera, HeartR, and Konar-MF VSD occluders; Ankura thoracic aortic aneurysm and abdominal aortic aneurysm stent graft systems; Futhrough endovascular needle systems; delivery systems, such as Fustar steerable and SteerEase introducers; Zoetrack guidewire; Aegisy vena cava filters; Cera vascular plug systems; AcuMark sizing balloons; HearTone implantable cardiac pacing system; and SeQure snare systems, as well as pacemakers.
LifeTech Scientific Corporation Fundamentals Summary
| 1302 fundamental statistics | |
|---|---|
| Market cap | HK$8.94b |
| Earnings (TTM) | HK$284.62m |
| Revenue (TTM) | HK$1.37b |
31.4x
P/E Ratio6.5x
P/S RatioIs 1302 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1302 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.27b |
| Cost of Revenue | CN¥271.54m |
| Gross Profit | CN¥995.64m |
| Other Expenses | CN¥732.40m |
| Earnings | CN¥263.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.057 |
| Gross Margin | 78.57% |
| Net Profit Margin | 20.77% |
| Debt/Equity Ratio | 0% |
How did 1302 perform over the long term?
See historical performance and comparison